This study is the first to explore the clinical study of neoadjuvant radiotherapy followed by chemotherapy combined with terriplizumab in breast cancer. Participants with locally advanced (T1c-T2(≥2cm) N1-2M0 or T3-4cN0-2M0) HR-positive and HER2-negative breast cancer were enrolled to evaluate the efficacy and safety of neoadjuvant radiotherapy followed by chemotherapy combined with triplimab in the treatment of locally advanced HR-positive and HER2-negative breast cancer. About 30 participants are planned to participate in this clinical study.
Age 18-75 years old, gender is not limited;
Histologically or pathologically confirmed non-specific invasive ductal carcinoma, histologically grade3, ER≥1%, HER2 negative, Ki-67>20%;
T1c-T2(≥2cm)N1-2M0 or T3-4cN0-2M0;
No previous treatment;
Those who are known to be allergic to recombinant humanized antiPD-1 monoclonal antibody drugs and their components;
Currently participating in and receiving other research treatment;
Previously received systematic treatment for breast cancer, including systematic chemotherapy, targeted therapy, immunotherapy, etc.;
Remote metastatic lesions of breast cancer were confirmed by imaging or pathology;